LGND

#3926
Ligand Pharmaceuticals Incorporated - Common Stock
2.3 2 USD
-99.01%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
2.32
2.32
Range Annuel
2.29
247.38
Changement quotidien
-99.01%
Changement Mensuel
-98.97%
Evolution sur 6 mois
-98.84%
Changement Annuel
-98.76%
Clôture Précédente
234.6 6
Open
2.3 2
Low
2.3 2
High
2.3 2
Volume
61
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Nouvelles